Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPM526000133 for psychosis in Alzheimer's disease (phase IIa, China)
CTR20254972Phase 2Active
- Sponsor
- Luye Pharma Group
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY03017 in Alzheimer's disease (AD), sponsored by Luye Pharma Group. Started Apr 2026; status: active.
02
Drugs
LY03017
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20254972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254972.